Pharmafile Logo
Pharmafocus logo
Advanced Search

Infections and infestations

Showing 15 posts of 42 posts found.

Enzymatica appoints Sana Alajmovic as new CEO

August 12, 2025
Research and Development Corporate, Enzymatica, Infections and infestations

The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step …

Appointment
az_vaccine

Rollout of world-first gonorrhoea vaccine programme begins under NHS

August 8, 2025
Medical Communications 10 Year Health Plan, Genito-Urinary system, Infections and infestations, NHS, gonorrhoea, sexual health, sexually transmitted infections, vaccination

From 4 August, sexual health clinics in England have been able to offer a free vaccine – the 4CMenB vaccine …

News
hospital

Sanome’s AI tool gains certification for early detection of hospital infections

August 7, 2025
Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections

Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …

News
lungs

M42 study highlights positive performance of AI model for tuberculosis screening

August 6, 2025
Research and Development AI, Infections and infestations, M42, X-ray, tuberculosis

Healthcare tech company, M42, has published results from one of the largest real-world studies of an artificial intelligence (AI)-powered tuberculosis …

News
Mosquito image

First malaria medicine for infants under 4.5kg receives approval

July 9, 2025
Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …

News

Ochre Bio appoints Elaine Sullivan as senior independent non-executive director

May 30, 2025
Research and Development Infections and infestations, Ochre Bio, Oncology, RNA therapeutics, Rare Diseases, appointment, senior independent non-executive director

Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a …

Appointment

Cold plasma therapy shown to be 100% effective against pneumonia-causing bacteria

May 19, 2025
Research and Development Infections and infestations, MRSA, Viromed Medical, intensive care, lung therapy, ventilator-associated pneumonia (VAP)

A breakthrough in lung therapy has been reported by German biotech company Viromed Medical whose cold plasma treatment has demonstrated …

News

ENA Respiratory appoints two strategic advisors to support leading project

May 7, 2025
Research and Development Ena Respiratory, Infections and infestations, Respirology, strategic adivsors

ENA Respiratory, focused on minimising the impact of viral respiratory infections, has announced the appointment of Kenny Simmen (pictured left) …

Appointment

FDA grants fast track designation to chlamydia vaccine candidate

March 28, 2025
Research and Development FDA, Infections and infestations, Sanofi, chlamydia, vaccination

The US Food and Drug Association (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention …

News

Antibacterial peptides instrumental in efficiency against resistant bacteria

November 18, 2024
Research and Development AMR, Chalmers Institute of Technology, Infections and infestations, MRSA, antibacterial peptides

This month, the Chalmers University of Technology in Sweden have published the results of a study demonstrating that resistant bacteria, …

News

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024
Research and Development COVID-19, EMA, Infections and infestations, coronavirus

AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …

News

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024
Research and Development Emmes Group, ILiAD Biotechnologies, Infections and infestations, Vaccine, whooping cough

ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead …

News

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024
Research and Development Gilead, HIV, Infections and infestations, clinical trial

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …

News

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

June 18, 2024
Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

Gilead’s Veklury recommended by NICE for COVID-19 treatment

April 9, 2024
Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026